Indivior Pharmaceuticals: Peers

The FY2025 (Dec) proxy of Indivior Pharmaceuticals names 20 peer companies for pay. Among Indivior Pharmaceuticals and these peers, CEO pay was 4th highest of 12 and total shareholder return was 5th highest of 12.

4th highest of 12in Indivior Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:

$6.9M$33.2M

5th highest of 12in Indivior Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:

$13$321

Pay peer group, FY2025 (Dec) proxy

Exelixis
PTC Therapeutics
Biomarin Pharmaceutical
United Therapeutics
Supernus Pharmaceuticals
Alnylam Pharmaceuticals
Ionis Pharmaceuticals
Ultragenyx Pharmaceutical
Alkermes plc.
Sarepta Therapeutics
Neurocrine Biosciences
Acadia PharmaceuticalsNot disclosedNot disclosed
Amneal PharmaceuticalsNot disclosedNot disclosed
Amphastar Pharmaceuticals, Inc.Not disclosedNot disclosed
Corcept TherapeuticsNot disclosedNot disclosed
Emergent BioSolutions Inc.Not disclosedNot disclosed
Exact Sciences CorporationNot disclosedNot disclosed
Intra-Cellular Therapies, Inc.Not disclosedNot disclosed
Novavax, Inc.Not disclosedNot disclosed
Pacira BioSciences, Inc.Not disclosedNot disclosed
20 companies

PSU comparator group

The companies that relative total shareholder return is measured against for performance stock units.

TSR Nasdaq Biotech Index (index)Not disclosedNot disclosed
1 company

Changes by year

FY2025 (Dec) proxy

  • RemovedAlmirall, S.A.pay peer groupFor 2025, the compensation committee removed Hikma Pharmaceuticals PLC, Swedish Orphan Biovitrum AB (publ), Almirall, S.A., Laboratorios Farmaceuticos Rovi, S.A., Myriad Genetics, Inc., and Ironwood Pharmaceuticals based on being headquartered in Europe, revenue range, or business fit
  • RemovedHikma Pharmaceuticals PLCpay peer groupFor 2025, the compensation committee removed Hikma Pharmaceuticals PLC, Swedish Orphan Biovitrum AB (publ), Almirall, S.A., Laboratorios Farmaceuticos Rovi, S.A., Myriad Genetics, Inc., and Ironwood Pharmaceuticals based on being headquartered in Europe, revenue range, or business fit
  • RemovedIronwood Pharmaceuticalspay peer groupFor 2025, the compensation committee removed Hikma Pharmaceuticals PLC, Swedish Orphan Biovitrum AB (publ), Almirall, S.A., Laboratorios Farmaceuticos Rovi, S.A., Myriad Genetics, Inc., and Ironwood Pharmaceuticals based on being headquartered in Europe, revenue range, or business fit
  • RemovedLaboratorios Farmaceuticos Rovi, S.A.pay peer groupFor 2025, the compensation committee removed Hikma Pharmaceuticals PLC, Swedish Orphan Biovitrum AB (publ), Almirall, S.A., Laboratorios Farmaceuticos Rovi, S.A., Myriad Genetics, Inc., and Ironwood Pharmaceuticals based on being headquartered in Europe, revenue range, or business fit
  • RemovedMyriad Genetics, Inc.pay peer groupFor 2025, the compensation committee removed Hikma Pharmaceuticals PLC, Swedish Orphan Biovitrum AB (publ), Almirall, S.A., Laboratorios Farmaceuticos Rovi, S.A., Myriad Genetics, Inc., and Ironwood Pharmaceuticals based on being headquartered in Europe, revenue range, or business fit
  • RemovedSwedish Orphan Biovitrum ABpay peer groupFor 2025, the compensation committee removed Hikma Pharmaceuticals PLC, Swedish Orphan Biovitrum AB (publ), Almirall, S.A., Laboratorios Farmaceuticos Rovi, S.A., Myriad Genetics, Inc., and Ironwood Pharmaceuticals based on being headquartered in Europe, revenue range, or business fit

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.